Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
20 mg sildenafil citrate by mouth
The First People's Hospital of Lianyungang
Pulmonary Hypertension
1 trial -
3-N-butylphthalide
The First People's Hospital of Lianyungang
Multiple System Atrophy
1 trial -
6-month course of antiandrogen drugs
The First People's Hospital of Lianyungang
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1 trial -
AZVUDINE
The First People's Hospital of Lianyungang
Chronic Hepatitis B
1 trial -
Acetazolamide Levamisole
The First People's Hospital of Lianyungang
HCC
1 trial -
Aerobic Exercise
The First People's Hospital of Lianyungang
Primary Hypertension
1 trial -
Alirocumab
The First People's Hospital of Lianyungang
Intracranial Atherosclerosis
1 trial -
Amlodipine
The First People's Hospital of Lianyungang
Sleep Apnea Syndrome
1 trial -
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Azathioprine
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Bedaquiline (B)
The First People's Hospital of Lianyungang
Pulmonary Tuberculosis
1 trial -
Botulinum Toxin type A (intradermal / submucosal injection at pain area)
The First People's Hospital of Lianyungang
Trigeminal Neuralgia
1 trial -
Busulfan (BU)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma
1 trial -
Camrelizumab
The First People's Hospital of Lianyungang
Esophageal Cancer
2 trials -
Capecitabine monotherapy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Capecitabine(Aibin)
The First People's Hospital of Lianyungang
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Endometrial Cancer
1 trial -
Clamp-Crushing technique
The First People's Hospital of Lianyungang
Hepatobiliary Disease
1 trial -
Continuous Gastrocnemius plane block with ropivacaine
The First People's Hospital of Lianyungang
Foot Ankle Injuries
1 trial -
Crystalline cellulose simple occlusive dressing
The First People's Hospital of Lianyungang
Split-thickness Skin Graft Donor Sites
1 trial -
Cytarabine
The First People's Hospital of Lianyungang
Leukemia
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources